BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 02:59:59 2024-06-04 EDT			5-day change	1st Jan Change
11.5 ^GBX	0.00%		+4.55%	+9.52%

05-31	EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend	AN
04-17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN

Bivictrix to raise more than GBP2 million via placing

July 19, 2023 at 09:14 am

Bivictrix Therapeutics PLC on Wednesday - Macclesfield, England-based biotechnology company focusing on cancer therapies - Announces a proposed fundraise of over GBP2 million by way of a conditional placing to investors. The placing will raise GBP1.2 million before expenses through the issue of 9.2 million shares at 13 pence per share. Adds the subscription of shares will raise around GBP800,000 before expenses through the issue of 6.8 million new shares. Says issue of shares is subject to shareholder approval at the general meeting set to take place on August 8.

Current stock price: 14.70 pence, up 1.4% on Wednesday

12-month change: down 28%

By Sabrina Penty; Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about BiVictriX Therapeutics Plc

EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend	05-31	AN
Bivictrix granted FDA orphan drug status for rare cancer treatment	04-17	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	04-17	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	12-05	CI
Bivictrix selects final sequences for lead tumour programme	11-30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	11-30	CI
BiVictriX patent boost; 4Global deal extended	11-15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	11-15	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	11-15	RE
Bivictrix says BVX001 increases survival rates by more than double	23-10-12	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	23-10-12	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	23-10-12	RE
Bivictrix hires new CFO as Alex Hughes steps down after seven months	23-10-03	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	23-10-03	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	23-10-03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	23-10-03	CI
AEW UK REIT appoints new chair; Oberon raises money	23-09-19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	23-09-19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-19	CI
AIM WINNERS & LOSERS: Jadestone Energy up on Montara repairs progress	23-08-23	AN
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23-08-23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23-08-23	MT
Bivictrix Therapeutics raises GBP2.1 million through fundraise	23-07-19	AN
Bivictrix to raise more than GBP2 million via placing	23-07-19	AN
Bivictrix Therapeutics hails positive data in final leukaemia study	23-07-17	AN

Chart BiVictriX Therapeutics Plc

Duration

Period

More charts

Company Profile

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.115 GBP

Average target price

0.66 GBP

Spread / Average Target

+473.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	+9.52%	12.14M
MODERNA, INC.	+48.64%	56.65B
IQVIA HOLDINGS INC.	-6.44%	39.44B
LONZA GROUP AG	+38.11%	39.03B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.75B
CELLTRION, INC.	-11.17%	26.86B
ALNYLAM PHARMACEUTICALS, INC.	-21.40%	19.03B
UNITED THERAPEUTICS CORPORATION	+25.64%	12.26B
BIO-TECHNE CORPORATION	+0.96%	12.28B
MEDPACE HOLDINGS, INC.	+27.04%	12.04B

Other Biotechnology & Medical Research